HealthPolitics

STAT+: Will the Treasury restrict U.S. investment in the Chinese biotech sector?

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 22/10/2026, 16:21:24 UTC.

Briefings

A 2026 article by STAT+ reports that telehealth companies are marketing off-label GLP-1 drugs for addiction treatment, including obesity medications, without waiting for FDA approval. The piece highlights startups like Quel, Livelyhood, and Choose Your Horizon, though it does not specify the number of companies or the extent of regulatory violations.

Key points

• Telehealth companies are marketing off-label GLP-1 drugs for addiction treatment, including obesity medications, without waiting for FDA approval.
• Startups including Quel, Livelyhood, and Choose Your Horizon are already marketing these prescriptions to people struggling with substance use.

Context

STAT+ is a news outlet that publishes articles on science and politics. The article discusses telehealth companies pushing GLP-1s for addiction treatment, noting that some are not waiting for FDA approval.

Limitations

Evidence is limited to a single article from October 2026. Specific numbers of companies, the number of off-label prescriptions, or the scope of regulatory violations are not provided. The article does not state whether these companies are violating regulations or if the FDA has explicitly blocked these marketing efforts.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 22/10/2026, 16:31:33 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeids2cl5objfwd2jhofvbnhi5u3mms5o3us3sp4yb5ev2u6nuh2dfa